ATE321143T1 - Genexpression in monocyten und makrophagen - Google Patents

Genexpression in monocyten und makrophagen

Info

Publication number
ATE321143T1
ATE321143T1 AT97920819T AT97920819T ATE321143T1 AT E321143 T1 ATE321143 T1 AT E321143T1 AT 97920819 T AT97920819 T AT 97920819T AT 97920819 T AT97920819 T AT 97920819T AT E321143 T1 ATE321143 T1 AT E321143T1
Authority
AT
Austria
Prior art keywords
polynucleotide
monocytes
macrophages
gene expression
trs
Prior art date
Application number
AT97920819T
Other languages
English (en)
Inventor
David Robert Greaves
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE321143T1 publication Critical patent/ATE321143T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
AT97920819T 1996-05-02 1997-05-02 Genexpression in monocyten und makrophagen ATE321143T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9609261.4A GB9609261D0 (en) 1996-05-02 1996-05-02 Gene expression in monocytes and microphages

Publications (1)

Publication Number Publication Date
ATE321143T1 true ATE321143T1 (de) 2006-04-15

Family

ID=10793127

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97920819T ATE321143T1 (de) 1996-05-02 1997-05-02 Genexpression in monocyten und makrophagen

Country Status (10)

Country Link
EP (1) EP0914456B1 (de)
JP (1) JP2001504683A (de)
AT (1) ATE321143T1 (de)
AU (1) AU732705B2 (de)
CA (1) CA2253322A1 (de)
DE (1) DE69735535T2 (de)
ES (1) ES2260793T3 (de)
GB (1) GB9609261D0 (de)
NZ (1) NZ332555A (de)
WO (1) WO1997042337A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1190083A2 (de) * 1999-07-06 2002-03-27 Glaxo Group Limited Auf dem aif4a genpromoter gegründete dna konstrukte
AU1358501A (en) * 1999-11-03 2001-05-14 Powderject Vaccines, Inc. Nucleic acid vaccine compositions having a mammalian cd80/cd86 gene promoter driving antigen expression
DE10001169A1 (de) * 2000-01-13 2001-07-26 Reske Kunz Angelika B Regulatorische Sequenz zur spezifischen Expression in dentritischen Zellen und deren Anwendungen
CN113621611B (zh) * 2021-04-26 2024-04-19 北京美康基免生物科技有限公司 一种髓系特异性启动子及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9305759D0 (en) * 1993-03-19 1993-05-05 Medical Research Council And T Hiv therapy method and agents
GB9319772D0 (en) * 1993-09-24 1993-11-10 Therexsys Ltd Therapeutic agent
US6110666A (en) * 1994-06-09 2000-08-29 Medical Research Council Locus control subregions conferring integration-site independent transgene expression abstract of the disclosure

Also Published As

Publication number Publication date
AU2705497A (en) 1997-11-26
GB9609261D0 (en) 1996-07-03
ES2260793T3 (es) 2006-11-01
WO1997042337A1 (en) 1997-11-13
CA2253322A1 (en) 1997-11-13
NZ332555A (en) 2000-03-27
EP0914456B1 (de) 2006-03-22
DE69735535T2 (de) 2006-09-07
EP0914456A1 (de) 1999-05-12
AU732705B2 (en) 2001-04-26
DE69735535D1 (de) 2006-05-11
JP2001504683A (ja) 2001-04-10

Similar Documents

Publication Publication Date Title
DE68910713D1 (de) Isolierung, Reinigung, Charakterisierung, Klonierung und Sequenzierung von N-alpha-Acetyltransferase.
BG101355A (en) Viral material and nucleotide fragments related to multiplesclerosis, for the diagnostics, prophylaxy and treatment of thisdisease
KR950700990A (ko) 신규의 분비단백질 에프-스폰딘의 클로닝, 발현 및 용도
SE8902532L (sv) Bestaemning av plasmaproteiner
DE69333639D1 (en) Trypsininhibitoren
ATE534742T1 (de) Polypeptide und nukleinsäuren von phorphorymonas gingivalis
DK0418945T3 (da) Forgreningsenzym og dets anvendelse
DE3789530D1 (de) Klonierung und Expression des sauren Fibroblastenwachstumsfaktors.
ES2058479T3 (es) Compuestos peptidicos.
EP0605073A3 (de) Molekuläre Klonierung und Expression von Neutral-Protease-Genen.
DE69735535D1 (de) Genexpression in monocyten und makrophagen
ATE356212T1 (de) O-fukosyltransferase
DE3585890D1 (de) Peptid und dafuer kodierendes gen.
BG101787A (en) Aprotinine options having improved properties
DE59206628D1 (en) Expression signalpeptid-freier staphylokinasen
DE3881123D1 (de) Klonieren von fuer einen antibakteriellen polypeptidvorlaeufer kodierender dna und expression des vorlaeufers.
RU97103147A (ru) Днк-последовательности, кодирующие человеческие протеины тх и ту, родственные конвергирующему интерлейкин-1-бета ферменту
HUP9900789A2 (hu) Lefelé irányuló szabályozásra rezisztens C3 konvertáz
FI884112A7 (fi) Aspergillus Nidulans isopenisilliini-N-syntetaasia koodaavat rekombinantti-DNA -ilmaisuvektorit ja DNA-sekvenssit.
DE69526087D1 (de) Or-1, ein wais-rezeptor der nuklearen rezeptoren familie
FI943866L (fi) Aspergillus-lajien eksopolygalaturonaasi-geenin kloonaus ja ilmentäminen
PT86034A (de) Klonierung und verwendung des transminase-gens ilve
FR2693464B1 (fr) Promoteur de levure et son utilisation.
HUP9901346A2 (hu) Deltap62 polipeptid és variánsai, ezeket kódoló nukleinsav-szekvenciák és felhasználásuk
ZA902436B (en) Purification of c.pseudotuberculosis toxin,and cloning and expression of toxin gene

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties